Oral therapy adherence and satisfaction in patients with multiple myeloma

Solano, M; Faure, Cyril; Loriod, Pierre; Pain, C; Maes, Anne-Cécile; Marguet, Pauline; Kroemer, Marie; Rumpler, Anne; Fontan, Jean; Deconinck, Eric; Limat, Samuel; Clairet, Anne-Laure

doi:10.1007/s00277-021-04543-7

Cited by 9 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to WHO, adherence to log-term therapy for chronic illnesses is about 50% in developed countries, which is a major challenge in the management of hematological malignancies. [3,20] Previous research in the area of mobile health has shown that the use of information and communication platforms can increase the patients' sense of autonomy and facilitate the disease management, resulting in higher QoL and adherence to treatment. [21] One interesting finding in our study was the impact of the number of previous treatment lines on the odds of being adherent to treatment, with patients who underwent more than 1 line of treatment having a much higher likelihood of adhering to the prescribed drug treatment.…”

Section: Discussionmentioning

confidence: 99%

“…[6,7] Often occurs that the mild drug-or disease-related symptoms that the patient perceives during the treatment period are underestimated, leading to a more severe symptomatology later on that could further impair the patient's adherence to treatment. [3] In addition, many anti-tumor therapies are now continuous treatments, making therapeutic adherence particularly relevant for patient outcomes. For instance, in a real-world study comparing ibrutinib and acalabrutinib, two drugs used to treat chronic lymphocytic leukemia, patients were more likely to be adherent to treatment (defined as ≥80% adherence) if they were being treated with ibrutinib, which is administered once daily, than if they were being treated with acalabrutinib, which needs to be administered twice daily.…”

Section: Preprint Settingsmentioning

confidence: 99%

“…[1] One of the pivotal factors influencing the long-term outcomes of patients facing these complex diseases is their adherence to treatment regimens and completion of the treatment protocol in a defined period. [1][2][3][4]…”

mentioning

confidence: 99%

See 2 more Smart Citations

Use of a Digital Medical Device to Improve Therapeutic Adherence in Patients with Hematological Malignancies: the MargheRITA Study (Preprint)

Ferri,

Dalto,

Romanelli

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Oncological conditions are a global health challenge, with a substantial number of deaths each year. Treatment adherence is crucial for improving patient outcomes in patients with hematological malignancies, but resource limitations and logistical challenges hinder optimal outpatient management. Digital health solutions, such as the Remote Intelligence for Therapeutic Adherence (RITA) software as medical device (SaMD), offer potential solutions by facilitating telemedicine visits and supporting patients in managing their treatment. OBJECTIVE To evaluate the performance and safety of RITA SaMD in improving patient adherence to treatment protocols for hematological malignancies. METHODS This prospective clinical investigation involved patients with hematological malignancies at ASST Santi Paolo e Carlo in Milan, Italy. The RITA SaMD Group used the RITA platform, while the Control Group comprised historical patients. The primary endpoint was therapeutic adherence to the prescribed drug treatment, defined as at least 80% of the prescribed dose intensity, at Month 3. Secondary endpoints included therapeutic adherence to the prescribed drug treatment at Month 1 and 2, emergency room (ER) visits, adverse events (AEs), and patient-reported outcomes (PROs). Multivariable logistic regression models were used to evaluate the effectiveness of RITA. RESULTS Between July and December 2022, 119 patients were included in the analysis (57 in the RITA SaMD Group and 62 in the Control Group). The probability of being adherent to treatment tended to be higher at all time points in the RITA SaMD Group compared with the Control Group (82.1% vs 80.7% at Month 1, 81.1% vs 76.3% at Month 2, and 85.2% vs 77.1% at Month 3). Multivariable analysis confirmed significantly improved adherence in the RITA SaMD Group at Month 3 [odds ratio (OR): 3.0, 95% confidence interval (CI): 1.0–8.8, P=0.042]. A total of 1476 self-reported AEs were collected through RITA SaMD usage, the majority (N=1080) being Grade 1 events. During the study visits, a total of 20 AEs was recorded by the study physician, 16 in the RITA SaMD Group and 4 in the Control Group. Of the recorded AEs during study visits, 14 were SAEs (11 in the RITA SaMD Group and 3 in the Control Group). None of the reported AEs was considered related to RITA SaMD usage. CONCLUSIONS The MargheRITA clinical investigation showed that after 3 months of using the RITA SaMD, patients with hematological malignancies had 3 times higher OR of being adherent to the prescribed treatment than the Control Group. The use of RITA SaMD facilitated the reporting of AEs and PROs, reinforcing the role of mobile health apps and software in optimizing patient outcomes. Further research is needed to fully understand its interdisciplinary potential and long-term impact on patient outcomes. CLINICALTRIAL ClinicalTrials.gov Identifier NCT05260203

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Preprint Settingsmentioning

confidence: 99%

See 1 more Smart Citation

Use of a Digital Medical Device to Improve Therapeutic Adherence in Patients with Hematological Malignancies: the MargheRITA Study (Preprint)

Ferri,

Dalto,

Romanelli

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…It has been shown that patients treated for chronic diseases, such as hypertension [3][4][5], diabetes [4,6,7], COPD [4,7], depression [4], epilepsy [8] or migraine [4], who are satisfied with medicines, are more compliant with treatment recommendations than those who are less satisfied. Oncology patients who are satisfied with their treatment also belong to the group of compliant patients [9,10].Additionally, it is well known that compliance with therapeutic recommendations determines the appropriate process of treatment, limiting the number of complications resulting from the progression of disease, and reducing the need for rehospitalization or hospitalization due to exacerbations.…”

Section: Introductionmentioning

confidence: 99%

Psychometric Properties of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) in Patients with Diabetes, Arterial Hypertension and Heart Failure

Świątoniowska-Lonc

Kołtuniuk

Jankowska‐Polańska³

2022

IJERPH

View full text Add to dashboard Cite

Background: Satisfaction with medicines is crucial in indicating patient experiences with the treatment which impact medicine adherence and compliance. Aim: The aim of this research was to adopt a general measure of patients’ satisfaction with medicines, the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q), to the Polish language (BMQ-PL). Materials and Methods: A total of 197 patients qualified for the research, with the following diagnoses: type 2 diabetes (n = 42), hypertension (n = 55) and heart failure (n = 100), aged 64.73 (SD = 13.27). The criterion-related validity was determined with the use of a Polish version of the Adherence to Refills and Medications Scale. Confirmatory and exploratory factor analyses were used. Results: The respondents’ mean score was 73.63 (SD = 18.42). Cronbach’s alpha for the entire instrument was 0.847. All items of the questionnaire were found to have a positive item–total correlation. A multifactorial linear regression model showed that a significant (p ˂ 0.05) independent variable increasing the SATMED-Q score for the whole group was educational level (vocational education R = 14.576; secondary education R = 14.055; higher education R = 19.372) and low adherence (R = −1.384) was a decreasing variable. Conclusions: The present findings indicate a high level of reliability and validity of the translated SATMED-Q questionnaire, fully comparable to that of the original. The questionnaire can be used for the assessment of satisfaction with medicines among Polish patients.

show abstract